Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II adjuvant furmonertinib after non-radical local therapy for EGFR-mutated stage IA non-small cell lung cancer
ChiCTR2400088570Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of furmonertinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Shanghai Chest Hospital. Primary endpoint: 3-year progression-free survival rate in the non-radical surgical resection group. Planned start Aug 2024; status: not yet recruiting.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400088570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088570.